Cyclacel Pharmaceuticals Statistics
Total Valuation
CYCC has a market cap or net worth of $26.44 million. The enterprise value is $22.74 million.
Important Dates
The next estimated earnings date is Tuesday, May 27, 2025, after market close.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | Apr 29, 2025 |
Share Statistics
CYCC has 12.96 million shares outstanding. The number of shares has increased by 56,772.43% in one year.
| Current Share Class | 12.96M |
| Shares Outstanding | 12.96M |
| Shares Change (YoY) | +56,772.43% |
| Shares Change (QoQ) | +35,793.02% |
| Owned by Insiders (%) | 152.84% |
| Owned by Institutions (%) | 0.18% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,869.73 |
| Forward PS | 256.63 |
| PB Ratio | 135.43 |
| P/TBV Ratio | 8.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,623.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.60, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.60 |
| Quick Ratio | 5.20 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1,950.23% and return on invested capital (ROIC) is -1,789.64%.
| Return on Equity (ROE) | -1,950.23% |
| Return on Assets (ROA) | -160.18% |
| Return on Invested Capital (ROIC) | -1,789.64% |
| Return on Capital Employed (ROCE) | -413.06% |
| Revenue Per Employee | $1,167 |
| Profits Per Employee | -$695,583 |
| Employee Count | 12 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CYCC has paid $572,000 in taxes.
| Income Tax | 572,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.88% in the last 52 weeks. The beta is 0.53, so CYCC's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -94.88% |
| 50-Day Moving Average | 4.15 |
| 200-Day Moving Average | 9.32 |
| Relative Strength Index (RSI) | 31.94 |
| Average Volume (20 Days) | 507,823 |
Short Selling Information
The latest short interest is 2.70 million, so 20.80% of the outstanding shares have been sold short.
| Short Interest | 2.70M |
| Short Previous Month | 27,619 |
| Short % of Shares Out | 20.80% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.45 |
Income Statement
In the last 12 months, CYCC had revenue of $14,000 and -$8.35 million in losses. Loss per share was -$0.04.
| Revenue | 14,000 |
| Gross Profit | 14,000 |
| Operating Income | -12.69M |
| Pretax Income | -22.73M |
| Net Income | -8.35M |
| EBITDA | -12.68M |
| EBIT | -12.69M |
| Loss Per Share | -$0.04 |
Full Income StatementBalance Sheet
The company has $3.45 million in cash and $9,000 in debt, giving a net cash position of $3.44 million or $0.27 per share.
| Cash & Cash Equivalents | 3.45M |
| Total Debt | 9,000 |
| Net Cash | 3.44M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 3.06M |
| Book Value Per Share | 0.01 |
| Working Capital | 3.05M |
Full Balance SheetCash Flow
| Operating Cash Flow | -10.75M |
| Capital Expenditures | n/a |
| Free Cash Flow | -10.75M |
| FCF Per Share | -$0.83 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -90,607.14% |
| Pretax Margin | -55,535.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |